Bergen, Norway, December 15th, 2023. Islay Ventures GmbH ("IV") a company
wholly owned and controlled by Lifecare CSO Prof. Dr. Dr. Med Andreas
Pfützner, has today reported to have sold 320,800 shares in the Company at an
average price of NOK 3.476. The transaction represents 12,24% of IV's original
holding.

After the transaction IV owns 2.299.699 shares in Lifecare, and IV has
accepted a lock-up period of 12 months for the remaining holdling. In addition
to the indirect holding through IV, Prof. Pfützner is allocated 1.048.058
share options in Lifecare.

The transaction is related to financial needs due to a restructuring of IV and
its subsidiaries, including transforming Prof. Pfützner's relationship to
Lifecare from a consultancy agreement to traditional employment with effect
from January 1st, 2024.

About us
Lifecare AS is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body.

Contacts
For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs,
asle.wingsternes@lifecare.no, +47 41 61 42 52

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 19 no. 3. The information was submitted for publication
at 2023-12-15 17:45 CET.